Related Experiment Videos
Insights
Coronary artery thrombosis, often linked to plaque rupture, can cause sudden cardiac death via microembolism. Further research is needed to understand its role in myocardial ischemia and death.
Area of Science:
- Cardiovascular Pathology
- Thrombosis Research
- Platelet Biology
Background:
- Coronary artery thrombosis typically follows atheromatous plaque rupture, leading to lumen narrowing and thrombus formation.
- Sudden cardiac death can occur without occlusive thrombi, suggesting microembolism from non-obstructing thrombi as a potential cause.
- Platelet aggregates in coronary circulation may induce arrhythmias, sudden death, and myocardial damage.
Purpose of the Study:
- To explore the role of coronary thrombosis and microembolism in sudden cardiac death and myocardial ischemia.
- To investigate the relationship between coronary artery plaque rupture, thrombus formation, and subsequent cardiac events.
- To evaluate the potential of platelet function tests and survival studies in predicting or understanding arterial thrombotic disease.
Main Methods:
- Autopsy observations of coronary arteries and myocardium.
- Review of experimental data on platelet aggregation and myocardial circulation.
- Analysis of clinical studies on platelet reactivity and therapeutic interventions.
Main Results:
- Occlusive thrombi correlate with full-thickness myocardial infarction, while non-occlusive thrombi are linked to subendocardial injury or no damage.
- Microembolism from mural thrombi is a plausible mechanism for sudden cardiac death and myocardial damage.
- Increased platelet reactivity is observed in thromboembolic episodes, but in vitro tests may not predict clinical disease.
Conclusions:
- Coronary thrombosis, particularly microembolism, is a significant factor in sudden cardiac death and myocardial ischemia.
- Further research, including well-designed clinical trials, is essential to elucidate the complex interplay between coronary thrombosis, microembolism, and cardiac outcomes.
- Platelet survival studies may offer more insight into arterial thrombotic disease than standard platelet function tests.
Abstract:
From many observations made at autopsy it is apparent that thrombosis in a coronary artery is usually, if not always, associated with rupture of an atheromatous plaque. The sequelae of such rupture include hemorrhage into the plaque with further narrowing of the lumen, formation of an occlusive thrombus or of a non-occlusive thrombus. A developing thrombus in an artery undergoes fragmentation with showering of the distal microcirculation by aggregates of platelets possibly with some admixture of fibrin. In many cases of sudden cardiac death associated with severe atherosclerotic stenosis of the coronary vessels, an occlusive thrombus is not found and the myocardium shows no morphological lesion or else focal patchy early damage in the subendocardial region. One possible mechanism that might explain these findings is microembolism from mural nonobstructing coronary thrombus. Such a mechanism is well established in transient ischemia of the brain and retina related to ulcerated atheroma of the internal carotid artery. Experimental observations indicate that platelet aggregates in the myocardial circulation cause arrhythmias, sudden death, vasculitis, and myocardial ischemic damage. Induction of an occlusive coronary artery thrombus is associated with development of an infarct involving the full thickness of the myocardium. A nonocclusive thrombus is associated with either no myocardial damage or focal subendocardial ischemic injury. It is possible that further aggregation of platelets may facilitate the extension of infarction subsequent to an occlusive event, although there is little evidence on this point. A number of clinical studies show increased platelet reactivity to agents causing aggregation, such as norepinephrine or collagen, in subjects experiencing thromboembolic episodes. It seems unlikely, however, that in vitro tests of platelet function can identify or predict clinical arterial thrombotic disease, although studies of platelet survival and turnover may be more helpful. There is also evidence that platelet survival may be prolonged by drugs having a therapeutic benefit in coronary artery disease and arterial thromboembolism. There is a need for better designed and coordinated clinical trials and for better experimental approaches to explore the relationships among coronary thrombosis, embolsim of the myocardial microcirculation, myocardial ischemia, and sudden death.